Rallybio Corporation (RLYB) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Rallybio Corporation (RLYB) closed at USD 16.91 on 2026-10-14, a change of +241.9 % over the past year, with a market capitalization of USD 89.12M.

Rallybio Corporation recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Rallybio Corporation key figures

Previous close

USD 16.91 (2026-10-14)

1-year change

+241.9 %

Market cap

USD 89.12M

Enterprise value

USD -3.77M

P/E ratio (trailing)

2.09

P/E ratio (forward)

-3.11

EPS (trailing)

8.01

EPS (forward)

-5.40

PEG ratio

n/a

Price to book

0.94

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

4.52

Employees

7

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Rallybio Corporation

Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Rallybio Corporation and compare it with other stocks.